Lentigo Treatment Guidelines

Introduction to Lentigo Treatment

The American Academy of Dermatology recommends 5-Fluorouracil (5-FU) for field treatment of lentigo, with a complete clearance rate of approximately 70% of lesions 1, 2

5-Fluorouracil (5-FU) is strongly recommended for field treatment of lentigo, with a complete clearance rate of approximately 70% of lesions 1, 2
The American Academy of Dermatology conditionally recommends Diclofenac gel for lentigo treatment, with a lower irritation profile than 5-FU, but less effective and carrying a black box warning for cardiovascular and GI side effects 1

The treatment approach should consider factors such as number and distribution of lesions, patient age and skin type, previous treatments and response, patient preference regarding side effects and treatment duration, and risk of progression (higher for lentigo maligna) 1
Evaluation of response after 12 weeks of topical therapy is recommended, with documentation using photographs before and during treatment 1
Confirming diagnosis with adequate biopsy and assessing patient factors such as age, general health, lesion location and size, cosmetic concerns, and comorbidities is essential, as recommended by the National Comprehensive Cancer Network 3, 4, 5

Complete surgical excision is the first-line treatment for lentigo maligna due to its superior efficacy in preventing progression to invasive melanoma, as recommended by the National Comprehensive Cancer Network 3, 4, 5
A 0.5 cm margin around visible lesions is recommended for in situ melanoma, including lentigo maligna, but larger margins may be necessary for large lesions 4, 5
Inadequate margins are the most common cause of recurrence, highlighting the importance of appropriate margin selection 3, 4

Topical imiquimod 5% cream is an emerging option for lentigo maligna, especially when surgery is not feasible, with a complete clinical clearance rate of approximately 75-90% 4, 5
Radiotherapy is a viable alternative with a 5% crude local failure rate, and a target margin of at least 10 mm around visible lesions is recommended 4
Combination therapy, such as cryotherapy + topical imiquimod, may be considered for resistant or numerous lesions, particularly for lentigo maligna 1

Patients should be educated on the importance of sun protection to prevent worsening of lesions and counteracting treatment effects 1
Realistic timeframes (6-12 weeks minimum) should be set for visible improvement, and patient expectations should be managed accordingly 1
Close follow-up is essential regardless of treatment modality due to the risk of recurrence or new primary lesions, with regular skin examinations, serial photographs for monitoring, and consideration of multiple post-treatment biopsies for non-surgical approaches 3, 4